When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 preclinical pancreatic cancer data.
Read original at benzingaStocks · News reference
Top 3 Health Care Stocks That May Keep You Up At Night In Q3
As of Aug. 27, 2026, three health care stocks are overbought and could be giving a real warning to momentum investors, according to the RSI indicator.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 12:46 PM
- Checked
- Aug 27, 2026, 12:46 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug
Shares of Revolution Medicines are trading higher Thursday morning as a wave of Wall Street firms issued price target increases following the commercial rollout of the company's first-in-class oncology therapy.
Read original at benzingaRevolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results
Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90% tumor inhibition and extended survival.
Read original at benzingaOppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $260
Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $230 to $260.
Read original at benzingaMizuho Maintains Outperform on Veeva Systems, Raises Price Target to $280
Mizuho analyst Steven Valiquette maintains Veeva Systems (NYSE:VEEV) with a Outperform and raises the price target from $270 to $280.
Read original at benzingaBMO Capital Maintains Market Perform on Veeva Systems, Raises Price Target to $270
BMO Capital analyst Sean Dodge maintains Veeva Systems (NYSE:VEEV) with a Market Perform and raises the price target from $175 to $270.
Read original at benzinga